Compare MRT & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRT | AARD |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | Turkey | United States |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 176.2M | 165.8M |
| IPO Year | 2021 | 2025 |
| Metric | MRT | AARD |
|---|---|---|
| Price | $1.95 | $5.30 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $3.58 | ★ $15.29 |
| AVG Volume (30 Days) | 46.0K | ★ 106.7K |
| Earning Date | 08-08-2018 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $72.36 | N/A |
| Revenue Next Year | $95.75 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.12 | $3.35 |
| 52 Week High | $2.75 | $17.94 |
| Indicator | MRT | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 64.77 | 44.11 |
| Support Level | $1.99 | $5.12 |
| Resistance Level | $2.29 | $6.43 |
| Average True Range (ATR) | 0.13 | 0.81 |
| MACD | 0.01 | -0.14 |
| Stochastic Oscillator | 92.73 | 22.17 |
Marti Technologies Inc is Turkiye's urban mobility platform, helping to solve the country's transportation needs through tech-enabled services powered by a single mobility super app. The Group aims to offer tech-enabled urban transportation services to consumers across Turkiye through three service offerings: ride-hailing, delivery, and two-wheeled electric vehicle services. The Group's ride-hailing service matches consumers with car, motorcycle, and taxi drivers. The Group's delivery service provides same-hour package delivery by leveraging the Group's existing network of car and motorcycle drivers and consumer base.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.